NeuroDex is a precision diagnostics company focused on unlocking the central nervous system through the analysis of neuron-derived extracellular vesicles isolated from blood. Its proprietary ExoSORT™ platform enables researchers and drug developers to measure brain-specific proteins and biomarkers from a routine blood draw, supporting earlier detection, target-engagement readouts, and treatment-response monitoring across neurodegenerative diseases including ALS, Alzheimer’s disease, and Parkinson’s disease.
NeuroDex Inc., 22 Strathmore Road, Natick, MA US 01760
NATICK, Mass., July 1, 2026 (SEND2PRESS NEWSWIRE) — NeuroDex, a precision diagnostics company specializing in the isolation and analysis of neuron-derived extracellular vesicles (NDEs) from blood, today announced new findings supporting NDE-associated TDP-43 as a treatment-responsive biomarker in amyotrophic lateral sclerosis (ALS).